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Background: Cervical carcinoma cells including those infected with the oncogenic human papilloma virus (HPV) and several cervi-
cal carcinoma cell lines show a strong expression of the CD40 receptor, unlike benign cervical epithelial cells infected with 
HPV. The functional relevance of this up-regulated expression in the tumor is not fully understood. Nevertheless, it might offer 
a unique possibility to target those malignant cells due to the antiviral and antitumoral effects of the CD40/CD40 ligand (CD40L) 
interactions. Aim: In vitro assessment of the effect of CD40L on HPV 18-P105 promoter activity and the subsequent release 
of IL-6 by the promoter transfected HeLaCD40 cells, which express CD40 constitutively. Material and Methods: Transfection 
of HeLaCD40 cells was achieved by electroporation after optimizing the parameters by the pCMV-β-Gal vector and β-Gal stain. 
Transfected HeLaCD40 cells were challenged with BHKCD40L and TNFα, in addition to BHKwt and medium alone as controls. HPV18-
P105 promoter activity was demonstrated by luciferase reporter gene assay while IL-6 was assessed by ELISA. Results: CD40/
CD40L interactions and TNFα treatment significantly reduced HPV18-P105 promoter activity (56.0 ± 10.2% and 64.1 ± 9.1% 
vs. control, respectively; p < 0.001). Likewise, IL-6, which is a sensitive cytokine of CD40 activation, was significantly increased 
in HeLaCD40 cells in the same experiments (2.7 fold after stimulation with BHKCD40L and 5.2 fold after stimulation with TNFα 
vs. control; p < 0.01 and p < 0.001, respectively). Conclusion: It is likely that the CD40/CD40L interactions and TNFα are effec-
tive against cervical carcinomas by repressing transcriptional activity of HPV promoter. This can result in new adjuvant treatments.
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INTRODUCTION
CD40 is a member of the TNFR family. It is ex-
pressed on B cells, monocytes, dendritic cells, and 
a variety of nonhemopoietic cells, including normal ke-
ratinocytes, tumor cells, and many in vitro transformed 
and carcinoma-derived cell lines. CD40L, a member 
of the TNF superfamily, is expressed primarily by acti-
vated T cells, activated B cells and platelets and under 
inflammatory conditions on monocytic cells, natural 
killer cells and mast cells. CD40/CD40L engagement 
is required for B-cell differentiation, isotype switching, 
maturation of dendritic cells and subsequent stimula-
tion of antigen-specific T cells [1].
The CD40/CD40L interactions in tumor cells seem 
to be pleiotropic and context dependent as it may not 
only inhibit tumor growth via immunologic mechanisms 
and induction of apoptosis but also may stimulate tu-
mor growth via various cytokines and growth factors 
including IL-6 and VEGF, among others [2]. Likewise, 
TNFα exerts selective direct tumor cytotoxicity but 
also promotes tumor development and metastases 
via NO release and angiogenesis [3]. In vivo and 
in vitro studies revealed that oncogenic human papil-
loma viruses (HPV) positive cervical carcinoma and 
HPV positive cervical carcinoma cell lines expressed 
CD40 at the high levels, in contrast to normal cervical 
epithelium and non-malignant keratinocyte cell lines 
transfected with HPV-DNA [4, 5]. This discrepancy 
may provide an explanation for persistence of HPV 
infection by evading the immune system as shown 
by increased production of IL-18 binding protein that 
antagonizes the inflammatory cytokine IL-18 and at-
tenuates the response to CD40 ligation and the capa-
city to attract peripheral blood mononuclear cells [6, 
7]. This immune escape may be the rational for the 
poor prognosis of cervical carcinoma in the presence 
of HPV-18 genotype [8]. The selective effect of TNFα 
on HPV infection is not known but previous studies 
have shown that both CD40/CD40L interactions in the 
presence of a protein inhibitor and TNFα exerted a di-
rect HeLaCD40 cytotoxicity, however it is unclear whether 
this effect also affects HeLaCD40 cells’ HPV infection [9].
The aim of the present work is to examine the func-
tional consequences of CD40/CD40L interactions and 
TNFα treatment on the HPV-18-p105 promoter activity 
of transfected HeLaCD40 cells in vitro.
MATERIALS AND METHODS
Cell lines and formaldehyde fixation. The cervi-
cal carcinoma cell line HeLaCD40 (for cloning of CD40-
cDNA and transfection see [10], CCL 2; American 
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Type Culture Collection, Kockville, MD) and the 
baby hamster kidney (BHKCD40L) cells, transfected 
with CD40L cDNA [11] (ACC 61; German Collection 
of Micro-organisms and Cell Cultures, Braunschweig, 
Germany) were cultured in DMEM supplemented with 
10% heat-inactivated fetal calf serum, 1 mM sodium 
pyruvate, 2 mM L-alanyl-L-glutamine and antibiotics 
(all from Life Technologies, Eggenstein, Germany). 
Formaldehyde-fixed BHKCD40L cells and the wild type 
variant BHKwt were prepared as described previ-
ously [9]. Formaldehyde fixation of BHK cells prevents 
cellular adhesion to culture plates and release of auto-
logous cytokines in an appreciable amount.
Transient transfection and assays. 1. Optimi-
zation of transfection efficiency by electroporation. 
The pCMV-β-Gal vectors and β-Gal stain method 
were used for adjustment and optimization of the 
electroporation variable parameters as previously 
described (Fig. 1, a) [12]. The voltage was varied 
at a range of 220 to 350 V with stepwise incre-
ments of 10 V, while the capacitance was tested 
at a range of 900 to 1400 µF with stepwise incre-
ments of 150 µF. The optimal parameters were found 
to be 300 V/1050 µF as demonstrated by the count and 
the density of the deep blue color of the transfected 
cells (Fig. 1, b, c). 2. Reporter gene assays (Luciferase 
assay). The luciferase expression test represents 
a reporter system for analysis of regulatory DNA se-
quence in which luciferase catalyzes the D-luciferin 
to emit a green luminescence that can be quantitatively 
measured. Electroporation cuvettes, each containing 
0.8 ml of HeLaCD40 cell suspension (adjusted at ca. 
8–9•106 cells/ml), to which 10 µg 4321-luc DNA 
(the entire HPV18 long control region (LCR) and the 
p105 promoter are conjugated on the luciferase gene) 
(Dr. Steger, Cologne, Germany) or 10 µg pCMV-β-Gal 
vector that served as a control were added. Mixtures 
were left at room temperature for 10 min and followed 
by application of the optimum electric pulses (300 V, 
1050 µF). Cells of 10 cuvettes were collected, gently 
mixed and seeded at equal number in 20 culture plates 
for 24 h followed by addition of formaldehyde-fixed 
BHKCD40L (6 plates, 2•106 cells/plate), formaldehyde-
fixed BHKwt (6 plates, 2•106 cells/plate) and TNFα 
(4 plates, each contains 1000 U/ml) while the re-
maining 4 plates contained medium only and served 
as controls. Culture plates were incubated at 37 °C for 
43 h followed by a gentle wash with warm medium 
to remove the BHK cells and TNFα. The transfected 
cells were washed with cold PBS and retrieved 
by a rubber scraper in 1.8 ml PBS. After centrifugation 
(250 g, 4 °C, 7 min) cells were resuspended in 50 µl ex-
traction buffer, lysed by 4 freeze-thaw cycles (each for 
2 min in liquid nitrogen at −196 °C and 2 min in water 
bath at 37 °C), and followed by ultracentrifugation 
(1400 g, 5 min at 4 °C). The extract was retrieved and 
kept on ice. The luciferase activity was measured 
by mixing 15 µl of the extract with 100 µl of the lucif-
erase assay buffer (containing rATP). After injection 
of 300 µl solvent (0.356 mM D-luciferin dissolved 
in luciferase buffer) the relative light units (RLU) were 
immediately measured in a LB 9501 luminometer 
(Berthold Technologies, Bad Wildbad, Germany). 
On the other hand, the control reaction consisted 
of 470 µl β-galactosidase-buffer, 100 µl ONPG so-
lution (4 mg/ml O-Nitrophenol-β-D-galactosidase 
in 0.1 M Na2HPO4-buffer, pH 7) and 30 µl cell extract 
which were incubated till they attain yellow color. Wells 
with β-Gal buffer and ONPG only served as controls. 
After stopping the reaction with 250 µl NaCO2, the 
fluorescence was measured at a wave length of 420 nm 
(Fig. 1, a).
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Fig. 1. Schematic representation of the experimental design, 
steps and methods (a). Detection of β-galactosidase activity 
after electrotransfection of HeLaCD40 cells (with pCMV-β-Gal; 
original magnification, × 40; b — electroporation parameters 
240 V and 1050 µF; c — electroporation parameters 300 V and 
1050 µF; the latter represents the optimal parameters as shown 
by the count and density of the blue dye)
Assessment of IL-6 by ELISA. Cells were seeded 
in 24-well plates at a density of 1.5•105 cells/well and 
were challenged after 24 h with BHKCD40L cells, BHKwt 
cells (each with 2•106 BHK/well), TNFα (1000 U/ml) 
or left with medium alone that served as a control. 
After 16 h, supernatants (SNs) were collected, cel-
lular debris was removed by centrifugation and the 
IL-6 contents were assessed by ELISA as previously 
described [11]. Briefly, Maxisorp plates (Nunc, Wi-
esbaden, Germany) were coated with 1 mg/ml anti-
IL-6 overnight. After blo cking of the plates for 1 h with 
PBS containing 0.5% BSA, 0.05% Tween 20 (Serva, 
Heidelberg, Germany), and 0.02% NaN3, SNs and 
serial dilutions of the recombinant human IL-6 (Tebu, 
Frankfurt, Germany) as standards were added for 
6 h. Plates were then incubated with polyclonal anti-
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IL-6 overnight (Tebu, Frankfurt, Germany) followed 
by a 2-hour incubation with peroxidase-labeled goat 
anti-rabbit F(ab) after which the substrate was applied 
and the absorbance was measured with an ELISA 
reader (SLT Lab Instruments, Hannover) at 405 nm 
(Fig. 1, a).
Statistical analysis. The mean and standard 
deviation of values obtained from each assay were 
calculated and the percentage decrease of luciferase 
assays was estimated. Unpaired Student t test was 
used to evaluate the difference between means and 
SD of reporter gene assay and IL-6.
RESULTS
CD40/CD40L interactions and TNFα treatment 
reduced the HPV18-P105-promoter activity in HeLa 
cells that expressed CD40 constitutively. To exa-
mine the possible regulatory effect of CD40L on the 
HPV18 control region, the HeLaCD40 cells transfected 
with reporter gene were stimulated for 43 h with 
formaldehyde-fixed BHKCD40L cells and also with 
TNFα. Formaldehyde-fixed BHKwt and medium alone 
served as controls. The activity of HPV18-P105-
promoter stimulated by formaldehyde-fixed BHKCD40L 
(RLU 2902.3 ± 291.49 vs. 4488 ± 459.62; p = 0.017) 
(in the four experiments) was repressed by a mean 
of 56 ± 10.2%, in comparison with BHKwt (RLU 5114 ± 
917.32 vs. 4488 ± 459.62; p = 0.45). Similarly, they 
were significantly stimulated by 1000 U/ml TNFα (RLU 
1765 ± 321.02 vs. 4488 ± 459.62; p = 0.02). On the 
other hand, formaldehyde-fixed BHKwt induced no sig-
nificant effect in comparison with control medium (RLU 
5114 ± 917.32 vs. 4488 ± 459.62; p = 0.45) (Fig. 2, a). 
It has been shown earlier that TNFα negatively regu-
lates the HPV16 gene expression [13]. In the pre sent 
work, activity of the HPV18-P105-promoter was 
repressed by TNFα by a mean of 64.9 ± 9.1% in com-
parison with medium. The standard deviations from 
several probes within each experiment were between 
1.0 and 10.1%. In contrast, the control pCMV-β-Gal 
vector-transfected HeLaCD40 cells incubated with 
formaldehyde-fixed  BHKCD40L or BHKwt cells or TNFα 
or medium alone showed similar and non-significant 
CMV promoter activity in all probes (p > 0.05).
CD40/CD40L interactions and TNFα treatment 
induce IL-6 release by the HeLaCD40 cells transfected 
with HPV18-P105. As IL-6 represents a very sensi-
tive parameter for activation of the CD40 and TNFα 
receptors, its concentration was determined upon 
stimulation. It was found that levels of IL-6 produced 
by HeLaCD40 cells increased significantly when chal-
lenged by both formaldehyde-fixed BHKCD40L and TNFα 
but not by formaldehyde-fixed BHKwt. The increase 
of IL-6 was up to 2.7 fold with BHKCD40L (p < 0.01) and 
5.2 fold with TNFα (p < 0.001) after 16 h incubation with 
HeLaCD40 transfected with the HPV18–105 (Fig. 2, b). 
This illustrates the efficient stimulation with the func-
tionally active CD40L and TNFα and also confirms 
the survival of the transfected HeLaCD40 cells and their 
sustained efficiency in releasing IL-6 upon stimulation.
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Fig. 2. Effect of CD40L and TNFα on transcription activity 
of HPV-LCR: a — transfected HeLaCD40 cells stimulated by TNFα 
and formaldehyde-fixed BHK cells for 43 h showed repression 
by BHKCD40L and TNFα but not BHKwt (*p < 0.01 vs. BHKwt and 
medium) as assessed by the luciferase activity; b — IL-6 was 
significantly elevated in the SNs of the corresponding experiment 
after 16 h incubation as assessed by ELISA (*p < 0.01 vs. BHKwt 
and **p < 0.001 vs. medium)
DISCUSSION
The functional relevance of the CD40/CD40L 
interac tions in malignant tumors is variable and likely 
context dependent. It has been shown that CD40/CD40L 
interac tions or up-regulation of CD40 correlated with 
poor prognosis in pancreatic ductal carcinoma [14] and 
non-small lung cancer [15], whereas CD40 ligation exerts 
antiproliferative effects and apoptosis induction in malig-
nant ovarian tumors [16] and melanoma cell lines [17]. 
Previous studies also showed that not only TNFα but also 
the CD40/CD40L interactions exert a direct cytotoxicity 
of HeLaCD40 cells in the presence of a protein inhibitor [9].
In vivo studies revealed that CD40 expression cor-
related with HPV positivity and VEGF expression as well 
as microvessel density, which provides explanation for 
its high levels in cervical carcinoma and its absence 
in cervicitis and normal cervix [18]. Persistent HPV 
infection of the cervical epithelium may lead to pro-
gression from cervical dysplasia to cancer over years 
or decades. Reso lution of epithelial HPV infection 
depends on complex interactions between the HPV-
infected keratinocytes and both host cell-mediated and 
humoral responses [19, 20]. Repression of HPV onco-
genes in HeLa cells resulted in the orderly restoration 
of dormant tumor suppressor pathways via mobilization 
of the p53 and Rb pathways to deliver growth inhibitory 
signals to the cells [21]. Interestingly, we could show that 
CD40/CD40L interactions and TNFα treatment resulted 
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in repression of the HPV18-p105-promoter in transfected 
HeLaCD40.This mechanism could be effective in early 
stages of HPV18-infection and could also contribute 
to the regression of HPV18-associated high-grade squa-
mous intraepithelial or tumor lesions expressing the HPV 
oncogene products. Accordingly, HPV-induced cancer 
therapeutic vaccines targeting the E6 and E7 onco-
proteins are combined with adjuvant and costimulatory 
anti-CD40 antibodies. The CD40/CD40L interactions and 
TNFα treatment exert several antitumor effects, directly 
by cytotoxicity and indirectly via repression of oncogenes 
and eliciting antigen-specific T cell responses [22].
Various cytokines have been implicated in the 
pathogenesis of cervical cancer, among which IL-6 has 
received particular attention. Similarly to CD40/CD40L 
interactions and TNFα treatment, IL-6 shows a context-
dependent pleiotropic effect as it promotes growth 
of certain tumors, such as cervical cancer, whereas 
it inhibits the growth of others. Recent studies showed 
that IL-6 favors proliferation and metastatic spread and its 
high expression in cervical malignant cells corresponds 
to bad prognosis. It has also been shown that IL-6 pro-
motes cervical tumorigenesis mainly by activating VEGF-
mediated angiogenesis via a STAT3 pathway [23]. In the 
present study, decreased activity of HPV18–105 pro-
moter upon BHKCD40L and TNFα treatment was associated 
with the significant increase of IL-6 levels. Although, the 
released IL-6 may provide neovascularization, promoting 
tumor growth and spread; this may also result in efficient 
recruitment of immune cells and better delivery of thera-
peutic cytotoxic drugs. Furthermore, certain cytotoxic 
drugs, such as zerumbone, not only induce cell death 
and apoptosis but also inhibit IL-6 release [24].
To conclude, the present study further confirms the 
antitumor properties of CD40/CD40L interactions and 
TNFα treatment in HPV-positive cervical carcinoma. 
Boosting of CD40 expression and release of TNFα might 
be considered as adjuvant therapies.
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